Early and intermediate follow-up results after treatment of degenerative disc disease with the Bryan cervical disc prosthesis: single- and multiple-level.

摘要

STUDY DESIGN: Our clinical study design was prospective, concurrently enrolled and single-center trial of the new functional intervertebral cervical disc prosthesis (Medtronic Sofamor Danek, Memphis, TN) in the treatment of patients with single-level and multiple-level degenerative disc disease of the cervical spine. OBJECTIVE: The study was designed to investigate the surgical technology skills and clinical effects of Bryan cervical disc prosthesis in Chinese, and to observe the stability and range of movement in the early and immediate postoperative period. SUMMARY OF BACKGROUND DATA: Recently, motion preservation has come to the forefront of emerging technologies in spine surgery. This is the important background information of the emergence of cervical arthroplasty as an alternative to arthrodesis that offers the promise of restoring normal spinal movement and reduces a kinematic strain on adjacent segments. METHODS: Nineteen patients (23 discs) had spinal arthroplasty with placement of the Bryan cervical artificial disc prosthesis in our hospital. Clinical and radiologic follow-up was performed. The radiographic parameters evaluated included the treated segments and the overall curvature of the cervical spine. RESULTS: All the patients were observed up from 8 months to 42 months (average 24 months). According to Odom's scale, all of 19 patients (23 levels) had excellent to good outcome. The range of movement recovered to the preoperative value during the follow up. The treated segment ultimately showed preservation of movement when compared with preoperative levels. No prosthesis subsidence or excursion was identified. CONCLUSION: Arthroplasty using the Bryan disc seemed to be safe and provided encouraging clinical and radiologic outcome in our study. Although early and intermediate results are promising, this is also a relatively new approach, long-term follow up studies are required to prove its efficacy and its ability to prevent adjacent segment disease.